Sign inJoin waitlistJoin the waitlist

Jordan Gauthier

Medical Director, Immunotherapy Long-Term Follow-Up Program, Fred Hutch · University of Washington School of Medicine

Credentials: · · ·

History

Immunotherapy Long-Term Follow-Up Program · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington School of Medicine
2017–2020
Immunotherapy Integrated Research Center
Internal Medicine
University of Washington School of Medicine
2014–2017
UNIV DE RENNES - (RENNES I), RENNES
2010–2014

Research

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Blood · 2019 · 359 citations
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Blood · 2019 · 306 citations
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
The Lancet Haematology · 2021 · 305 citations

CT
Cameron Turtle
31 papers
Mazyar Shadman
28 papers
David Maloney
27 papers
Brian Till
17 papers
Emily Liang
17 papers · 17 as a resident
Andrew Portuguese
14 papers · 4 as a fellow
Damian Green
14 papers
Joshua Hill
14 papers
Stanley Riddell
13 papers
AC
Andrew Cowan
12 papers
Erik Kimble
12 papers · 1 as a fellow
JH
Jennifer Huang
12 papers · 12 as a fellow

Clinical trials

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Principal investigator · Withdrawn · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2025–2027
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2021–2024
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2017–2024
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2016–2021